
Over the Hill and (still) far away for UK biotech companies
By Simon Goldman (pictured), Investment Director, AlbionVC – This month’s Lord Hill review will do little to halt UK biotech companies’ exodus to public markets across the pond. The review seeks to ease the path to a London Stock Exchange listing and thus increase growing businesses’ access to UK capital markets.

